Teresa Rampino

Dr. Teresa Rampino

orcid

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2006 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
GGGiuseppe Gerna
Giuseppe Gerna
DLDaniele Lilleri
Daniele Lilleri
CFChiara Fornara
Chiara Fornara
GCG. Comolli
G. Comolli
LLL. Lozza
L. Lozza
TRTeresa Rampino
Teresa Rampino
Absolute and human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T-cell counts were monitored in 38 solid organ (20 heart, 9 lung and 9 kidney) transplant recipients during the first year after transplantation by a novel assay based on T-cell stimulation with HCMV-infected autologous dendritic cells. According to the pattern of T-cell restoration occurring either within the first month after transplantation or later, patients were classified as either early (n = 21) or late responders (n = 17). HCMV-specific CD4+ and CD8+ T-cell counts were consistently lower in late compared to early responders from baseline through 6 months after transplantation. In addition, in late responders, while HCMV infection preceded immune restoration, HCMV-specific CD4+ restoration was significantly delayed with respect to CD8+ T-cell restoration. The number of HCMV-specific CD4+ and CD8+ T-cells detected prior to transplantation significantly correlated with time to T-cell immunity restoration, in that higher HCMV-specific T-cell counts predicted earlier immune restoration. Clinically, the great majority of early responders (18/21, 85.7%) underwent self-resolving HCMV infections (p = 0.004), whereas the great majority of late responders (13/17, 76.5%) were affected by HCMV infections requiring antiviral treatment (p = <0.0001). Simultaneous monitoring of HCMV infection and HCMV-specific T-cell immunity predicts T-cell-mediated control of HCMV infection.

21 June 2017 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
MGMarilena Gregorini
Marilena Gregorini
VCValeria Corradetti
Valeria Corradetti
EPELEONORA FRANCESCA PATTONIERI
ELEONORA FRANCESCA PATTONIERI
CRChiara Rocca
Chiara Rocca
SMSamantha Milanesi
Samantha Milanesi
TRTeresa Rampino
Teresa Rampino
Kidney donation after circulatory death (DCD) is a less than ideal option to meet organ shortages. Hypothermic machine perfusion (HMP) with Belzer solution (BS) improves the viability of DCD kidneys, although the graft clinical course remains critical. Mesenchymal stromal cells (MSC) promote tissue repair by releasing extracellular vesicles (EV). We evaluated whether delivering MSC‐/MSC‐derived EV during HMP protects rat DCD kidneys from ischaemic injury and investigated the underlying pathogenic mechanisms. Warm ischaemic isolated kidneys were cold‐perfused (4 hrs) with BS, BS supplemented with MSC or EV. Renal damage was evaluated by histology and renal gene expression by microarray analysis, RT‐PCR. Malondialdehyde, lactate, LDH, glucose and pyruvate were measured in the effluent fluid. MSC‐/EV‐treated kidneys showed significantly less global ischaemic damage. In the MSC/EV groups, there was up‐regulation of three genes encoding enzymes known to improve cell energy metabolism and three genes encoding proteins involved in ion membrane transport. In the effluent fluid, lactate, LDH, MDA and glucose were significantly lower and pyruvate higher in MSC/EV kidneys as compared with BS, suggesting the larger use of energy substrates by MSC/EV kidneys. The addition of MSC/EV to BS during HMP protects the kidney from ischaemic injury by preserving the enzymatic machinery essential for cell viability and protects the kidney from reperfusion damage.

5 November 2009 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
PDF file
RCRosannna Coppo
Rosannna Coppo
RCR. Camilla
R. Camilla
AAA. Amore
A. Amore
LPL. Peruzzi
L. Peruzzi
VDV. Daprà
V. Daprà
ACA. Dal Canton
A. Dal Canton
We investigated Toll-like receptors (TLR-3, -4 and -7) expression in circulating mononuclear cells of patients with immunoglobulin A nephropathy (IgAN), a disease with debated relationships with mucosal immunity. TLR-4 expression (detected by fluorescence activated cell sorter) and mRNA transcriptional levels (Taqman) were significantly higher in patients with IgAN than in healthy controls (P = 0·00200 and P = 0·0200). TLR-3 and TLR-7 were not modified significantly. In IgAN patients proteinuria was correlated significantly with TLR-4 expression (P = 0·0312). In a group of nephrotic syndromes, TLR-3, -4 and -7 expression was similar to healthy controls. A significant difference in TLR-4 expression and mRNA levels was found between very active IgAN patients (proteinuria > 1 g/1·73 m2/day in association with severe microscopic haematuria) and inactive patients (proteinuria < 0·5 g/1·73 m2/day, with absent or minimal haematuria). No correlation with levels of aberrantly glycosylated IgA1, age, renal biopsy features or therapy was found. This study shows for the first time an up-regulation of TLR-4 in circulating mononuclear cells of patients with IgAN, particularly in association with proteinuria and heavy microscopic haematuria.

1 December 1999 in Kidney International
Verified
Journal Article
Closed access
TRTeresa Rampino
Teresa Rampino
EAEloisa Arbustini
Eloisa Arbustini
Marilena GregoriniMarilena Gregorini
Marilena Gregorini
PGPaola Guallini
Paola Guallini
CLCarmelo Libetta
Carmelo Libetta
ACAntonio Dal Canton
Antonio Dal Canton

1 May 2010 in Transplantation Proceedings
Verified
Journal Article
Closed access
MMM. De Martino
M. De Martino
SZS. Zonta
S. Zonta
TRTeresa Rampino
Teresa Rampino
Marilena GregoriniMarilena Gregorini
Marilena Gregorini
FFFrancesco Frassoni
Francesco Frassoni
MAM. Alessiani
M. Alessiani

1 August 1992 in Kidney International
Verified
Journal Article
Closed access
BMBruno Memoli
Bruno Memoli
CLCarmelo Libetta
Carmelo Libetta
TRTeresa Rampino
Teresa Rampino
ACAntonio Dal Canton
Antonio Dal Canton
GCGiuseppe Conte
Giuseppe Conte
VAVittorio E. Andreucci
Vittorio E. Andreucci